07:00 , Oct 15, 2015 |  BC Innovations  |  Finance

Public-Private Partnership Roundup

PPP activity was down slightly in 3Q15 compared with the previous quarter, with 61 partnerships announced during that span. Big pharmas and biotechs continue to pair up with public and academic institutions at a high...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

NeoGenomics management update

NeoGenomics Inc. (NASDAQ:NEO), Fort Myers, Fla.   Business: Genomics, Diagnostic, Supply/Service   Hired: Robert Shovlin as COO, effective Oct. 13, formerly chief development officer of Bostwick Laboratories Inc.  ...
00:53 , Jan 4, 2014 |  BC Extra  |  Financial News

Metabolon raises $15 million in E round

Metabolomics company Metabolon Inc. (Durham, N.C.) raised $15 million in a series E round led by new investor Camden Partners. New investor Sumitomo Corp. (Tokyo:8053) also participated, along with existing investors Aurora Funds; Harris &...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Bostwick, Metabolon sales and marketing update

Bostwick will exclusively market Metabolon's Prostarix prostate cancer diagnostic in the U.S. The test is a non-invasive test that quantifies sarcosine and other biomarkers excreted into urine to stratify prostate cancer risk. Bostwick will offer...
07:00 , Jun 28, 2012 |  BC Innovations  |  Targets & Mechanisms

Endostatin for fibrosis

University of Pittsburgh School of Medicine researchers have shown that a compound derived from endostatin prevented and reversed organ fibrosis in mice. 1 The findings may suggest a new use for endostatin, which is approved...
07:00 , Jun 14, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Dermatology; pulmonary fibrosis Not applicable In vitro and mouse studies suggest the C-terminal domain of endostatin could help treat and prevent organ fibrosis. In an...
07:00 , Aug 2, 2010 |  BC Week In Review  |  Company News

Commonwealth Biotechnologies supply/service news

Commonwealth said it plans to divest its remaining assets to create a debt-free shell and plans to then seek a merger opportunity. The company will seek to sell its Richmond real estate and its Mimotopes...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Company News

Commonwealth Biotechnologies, Bostwick deal

Bostwick completed its previously announced acquisition of Commonwealth's Fairfax Identity Laboratories and CBI Services divisions for $1.1 million in cash plus lease payments for five years. Commonwealth said the deal will support its ongoing acquisition...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Company News

Bostwick, Sangretech deal

The partners added undisclosed amendments to a 2007 licensing deal that granted Bostwick's Bostwick Scientific research division rights to use Sangretech's dendritic cell technology to develop and commercialize Bostwick's VDC2008 . Bostwick will start a...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Company News

Commonwealth Biotechnologies, GL Biochem (Shanghai) deal

Discovery and development services company Commonwealth will acquire peptide supply company GL Biochem in a stock deal. GL Group shareholders will own 68-80% of Commonwealth's share capital on a fully-diluted basis after the deal. Commonwealth...